Tetrazole

Tetrazole

SCHEMBL1613289

O=P(O)(O)Oc1cc2c(Br)c(Cl)ccc2[nH]1.c1nnn[nH]1.c1nnn[nH]1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9538412 0.88 INPPL1 (0.32)
Tetrazole SCHEMBL5041698 0.86
Tetrazole SCHEMBL5041695 0.86
Tetrazole SCHEMBL3922918 0.86
Tetrazole SCHEMBL6400674 0.85
Tetrazole SCHEMBL10416579 0.73 FLT3 (0.36)
SCHEMBL79536 0.72 DAO (0.33)
Phosphoric Acid SCHEMBL7161584 0.71 NR4A2 (0.39)
SCHEMBL6507136 0.69 DAO (0.50)
Tetrazole SCHEMBL28110299 0.68 F7 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130251735-A1 SCLEROSTIN AND THE INHIBITION OF WNT SIGNALING AND BONE FORMATION ENZO BIOCHEM INC (US) 2013-09-26 US disclosed
US-8461155-B2 Binding to LRP5 or LRP6 receptor; promoting growth with DAN family bone morphogenetic protein antagonist UNIVERSITY OF CONNECTICUT (US) 2013-06-11 US disclosed
EP-2248528-B1 Use of compositions comprising Dkk2 and fragments thereof for the stimulation or enhancement of bone formation ENZO THERAPEUTICS INC (US) 2013-01-02 EP disclosed
US-8343922-B2 Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells ENZO BIOCHEM, INC. (US) 2013-01-01 US disclosed
US-20120115787-A9 Sclerostin and the inhibition of WNT signaling and bone formation CONNECTICUT UNIVERSITY OF 2012-05-10 US disclosed
US-20110086021-A1 Sclerostin and the inhibition of WNT signaling and bone formation ENZO THERAPEUTICS, INC., C/O ENZO BIOCHEM, INC. (US) 2011-04-14 US disclosed
EP-2248528-A1 Use of compositions comprising Dkk2 and fragments thereof for the stimulation or enhancement of bone formation ENZO THERAPEUTICS, INC. (US) 2010-11-10 EP disclosed
US-20100074891-A1 Sclerostin and the inhibition of Wnt signaling and bone formation WU DIANQING DAN 2010-03-25 US disclosed
EP-1755643-A4 COMPOSITIONS AND METHODS FOR THE STIMULATION OR ENHANCEMENT OF BONE FORMATION AND THE SELF-RENEWAL OF CELLS ENZO THERAPEUTICS INC (US) 2009-08-19 EP disclosed
EP-1883418-A2 SCLEROSTIN AND THE INHIBITION OF WNT SIGNALING AND BONE FORMATION ENZO BIOCHEM, INC. (US) 2008-02-06 EP disclosed
EP-1755643-A2 COMPOSITIONS AND METHODS FOR THE STIMULATION OR ENHANCEMENT OF BONE FORMATION AND THE SELF-RENEWAL OF CELLS ENZO THERAPEUTICS, INC. (US) 2007-02-28 EP disclosed
WO-2006102070-A2 SCLEROSTIN AND THE INHIBITION OF WNT SIGNALING AND BONE FORMATION ENZO BIOCHEM, INC. (US) 2006-09-28 WO disclosed
US-20060030523-A1 Sclerostin and the inhibition of WNT signaling and bone formation WU DIANQING D 2006-02-09 US disclosed
WO-2005112981-A2 COMPOSITIONS AND METHODS FOR THE STIMULATION OR ENHANCEMENT OF BONE FORMATION AND THE SELF-RENEWAL OF CELLS ENZO THERAPEUTICS, INC. (US) 2005-12-01 WO disclosed
US-20050261181-A1 Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells ENZO LIFE SCIENCES, INC. 2005-11-24 US disclosed